Fingolimod Phosphate Attenuates Oligomeric Amyloid β–Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons

Yukiko Doi, Hideyuki Takeuchi*, Hiroshi Horiuchi, Taketo Hanyu, Jun Kawanokuchi, Shijie Jin, Bijay Parajuli, Yoshifumi Sonobe, Tetsuya Mizuno, Akio Suzumura

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Japan

Abstract
The neurodegenerative processes that underlie Alzheimer’s disease are mediated, in part, by soluble oligomeric amyloid β (sAβ) a neurotoxic protein that inhibits hippocampal long-term potentiation, disrupts synaptic plasticity, and induces the production of reactive oxygen species. Here we show that the sphingosine-1-phosphate (S1P) receptor (S1PR) agonist fingolimod phosphate (FTY720-P)–a new oral drug for multiple sclerosis–protects neurons against oligomeric amyloid β–induced neurotoxicity. We confirmed that primary mouse cortical neurons express all of the S1P receptor subtypes and FTY720-P directly affects the neurons. Treatment with FTY720-P enhanced the expression of brain-derived neurotrophic factor (BDNF) in neurons. Moreover, blocking BDNF-TrkB signaling with a BDNF scavenger, TrkB inhibitor, or ERK1/2 inhibitor almost completely ablated these neuroprotective effects. These results suggested that the neuroprotective effects of FTY720-P are mediated by upregulated neuronal BDNF levels. Therefore, FTY720-P may be a promising therapeutic agent for neurodegenerative diseases, such as Alzheimer’s disease.

Introduction
Alzheimer’s disease (AD) is the most common cause of dementia [1,2]. Senile plaques consisting of insoluble fibrillar amyloid β (Aβ) are pathologic hallmarks of AD. Aβ is formed after sequential cleavage of amyloid precursor protein and is secreted to the extracellular space. Aβ has a strong fibrillogenic property, and soluble Aβ monomers gradually convert to oligomers and ultimately to insoluble fibrils. Soluble oligomeric Aβ (sAβ) is considered to be more important in the pathogenesis of AD than fibrillar Aβ, because sAβ is more neurotoxic [3,4]. Naturally secreted sAβ inhibits hippocampal long-term potentiation and disrupts synaptic plasticity [2]. In addition, sAβ induces elevation of reactive oxygen species levels in neurons, leading to neuronal death [5].

Fingolimod is a new oral drug for multiple sclerosis [6–9]. Fingolimod was synthesized by modifying myriocin, which is derived from Isaria sinclairii [10]. Because fingolimod is a structural analogue of sphingosine, it is phosphorylated by sphingosine kinase in vivo. Once phosphorylated, fingolimod binds to sphingosine-1-phosphate (S1P) receptor 1 (S1P1) on the surface of lymphocytes, and the receptors are internalized. These lymphocytes can no longer move out of lymphoid tissues. Therefore, fingolimod phosphate (FTY720-P) prevents autoreactive lymphocytes from infiltrating the central nervous system (CNS) and suppresses subsequent neuroinflammation [11–13].

Many studies have shown that S1PRs are widely expressed in many cell types, including neurons, astrocytes, microglia, and oligodendrocytes [14]. The functions of these receptors have not been elucidated completely, however. There are five S1PR subtypes: S1P1, S1P2, S1P3, S1P4, and S1P5. FTY720-P binds to all S1PR subtypes except S1P2 [15,16]. Previous studies demonstrated that FTY720-P directly induced oligodendrocytes to promote remyelination [17] and enhanced neuroprotective effects in astrocytes [18]. Moreover, we have recently showed that FTY720-P augmented microglial neuroprotective effects by downregulation of pro-inflammatory cytokines and upregulation of neurotrophic factors [19]. However, it is still uncertain whether FTY720-P directly affects neurons. S1P reportedly promotes neurogenesis from proliferation of neuronal progenitor cells [20]. S1P also contributes to the migration of neuronal stem/progenitor cells [21]. Therefore, FTY720-P may directly affect neurons. Here, by assessing the effects of FTY720-P on neurons, we show that FTY720-P directly upregulates neuronal brain-derived neurotrophic factor (BDNF) production to attenuate oAβ–induced neurotoxicity.

Methods
Preparation of fingolimod phosphate
Fingolimod phosphate (FTY720-P) was kindly provided by Tanabe Mitsubishi Pharma (Osaka, Japan). FTY720-P was dissolved in 80% ethanol containing 2 mM NaOH.
Preparation of oligomeric Aβ1-42

Soluble oligomeric Aβ1-42 (oAβ1-42) was prepared as described previously [4,22]. Briefly, synthetic human Aβ1-42 (Peptide Institute, Osaka, Japan) was dissolved in 100% 1,1,1,3,3,3-hexafluoro-2-propanol and dried to completely remove the solvent. The obtained film was resuspended in dimethyl sulfoxide, and diluted with Dulbecco’s Modified Eagle Medium/F12 (Invitrogen, Carlsbad, CA, USA) at a concentration of 100 μM. This solution was incubated at 4°C for 24 h to obtain oAβ. A final concentration of 5 μM oAβ1-42 was used for all experiments. The oligomerization of oAβ was characterized by Western blotting as below.

Neuronal cultures

Protocols for animal experiments were approved by the Animal Experiment Committee of Nagoya University [permission number: 12122]. Primary mouse cortical neurons were prepared as described previously [4,23]. Briefly, cerebral cortices were isolated from embryonic day 17 C57BL/6j mouse embryos, minced and treated with dissociation solution (Sumitomo Bakelite, Akita, Japan). Resulting neurons were resuspended in Nerve Culture Medium™ (Sumitomo Bakelite), plated on polyethyleneimine-coated glass coverslips (Asahi Techno Glass, Chiba, Japan) at a density of 5 × 10^5 cells/well in 96-well multidishes, 5 × 10^4 cells/well in 24-well multidishes or 5 × 10^5 cells/well in 6-well multidishes, and incubated at 37°C in an atmosphere containing 5% CO2 at 100% humidity. The purity of the cultures was >95% based on NeuN-specific immunostaining. Neurons were used at 14 days in vitro for the following assessments.

RNA extraction and reverse transcription-polymerase chain reactions (RT-PCRs)

To assess the neuronal expression of S1PRs, neurons at 14 days in vitro were stimulated with 5 μM oAβ1-42 for 6 h. Expression of mRNA encoding S1P1, S1P2, S1P4, S1P5, and S1P6 was detected using RT-PCRs. Total RNA was isolated with an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and reverse transcribed with SuperScript II (Invitrogen). PCRs were performed using Blend Taq (Toyobo, Osaka, Japan). The following sense and antisense primers were used:

- **S1P1 sense**: 5’-GACCATGGCATTAAACTGACCTT-3’
- **S1P1 antisense**: 5’-TGTAGTTTCTATCTTGGAGCATGG-3’
- **S1P2 sense**: 5’-AAGTTTCCACCTGACGAATGTC-3’
- **S1P2 antisense**: 5’-TAGATGACAGAATGAGCATGG-3’
- **S1P3 sense**: 5’-CTCTTCTTGTGGTACCTCTGCT-3’
- **S1P3 antisense**: 5’-TCATGAGGAAGAGTATAAAA-3’
- **S1P4 sense**: 5’-GTGACTACTCTGCCCTGCTGAA-3’
- **S1P4 antisense**: 5’-GATGGAGGAATGAGCATGG-3’
- **S1P5 sense**: 5’-GGCGTCCTAAGCAGTTCCAG-3’
- **S1P5 antisense**: 5’-GGCGTCCTAAGCAGTTCCAG-3’
- **S1P6 sense**: 5’-CCTGCTCTCCATCACCTTCTTG-3’
- **S1P6 antisense**: 5’-CTGCTCTCCATCACCTTCTTG-3’

To assess the neuronal expression of neurotrophic factors, neurons at 14 days in vitro were stimulated with 1–100 pM FTY720-P for 6 h. Total RNA was isolated with an RNeasy Mini Kit (Qiagen) and reverse transcribed with SuperScript II (Invitrogen). Expression levels of mRNA encoding BDNF, nerve growth factor (NGF), and neurotrophin-3 (NT-3) were evaluated using quantitative PCR (qPCR), which was performed on the cDNA using a Rotor-Gene Q (Qiagen) and a TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA, USA). The mouse gene-specific primers and probes were obtained from Applied Biosystems: BDNF (Mm00443039_m1), NT-3 (Mm00435413_s1), HPRT1 (Mm01545399_m1) and GAPDH (Mm99999915_g1). Gene expression values were determined by using the ΔΔC_T method. The genes of interest were standardized to the geometric mean of HPRT1 and GAPDH. Assays were carried out in six independent trials.

Western blotting

To confirm the oligomerization, oAβ1-42 was also dissolved in Laemmli sample buffer. Cell lysates were used to examine S1PR subtypes and BDNF production. The neurons at 14 days in vitro were treated with 5 μM oAβ or 100 pM FTY720-P for 24 h. Cells were lysed in lysis buffer (50 mM Tris-HCl at pH 7.6, 1% Nonidet P-40, 150 mM NaCl, 2 mM EDTA, and protease inhibitor mixture (Complete Mini EDTA-free, Roche, Germany)). Soluble fractions were collected following centrifugation for 5 min at 10,000 rpm and the protein concentration was determined in a bicinchoninic acid assay (Thermo Fisher Scientific, Rockford, IL, USA). The soluble fractions of the cell lysates or neuronal culture supernatant were dissolved in Laemmli sample buffer.

Forty micrograms of cell lysate protein or 300 ng of oAβ1-42 dissolved in Laemmli sample buffer were separated on 4–20% SDS-polyacrylamide gels (Mini-Protein TGX™, Bio-Rad, Hercules, CA, USA), and transferred to Hybond-P polyvinylidene difluoride membranes (GE Healthcare, Buckingham, UK). The membranes were blocked with 1% skim milk in Tris-buffered saline containing 0.05% Tween-20 for 1 h at room temperature, and then incubated overnight at 4°C with rabbit anti-S1P1 polyclonal antibodies (1:200; Cayman Chemical, Ann Arbor, MI, USA), rabbit anti-S1P2 polyclonal antibodies (1:500; Cayman Chemical), rabbit anti-S1P3 polyclonal antibodies (1:200; Cayman Chemical), rabbit anti-S1P4 polyclonal antibodies (1:100; Cayman Chemical), rabbit anti-S1P5 polyclonal antibodies (1:200; Cayman Chemical), rabbit anti-BDNF polyclonal antibodies (N-20; 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-Aβ monoclonal antibodies (6E10) (1:1000; Covance, Princeton, NJ, USA), mouse anti-GAPDH monoclonal antibodies (3H12) (1:1000; MBL, Nagoya, Japan), or mouse anti-β-actin monoclonal antibodies (AG-15) (1:2000; Sigma) followed by horseradish peroxidase–conjugated secondary antibodies (1:5000; GE Healthcare, UK) for 1 h at room temperature. The signals were visualized using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific), and quantified using a CS Analyzer 3.0 system (Atto, Tokyo, Japan). Assays were carried out in six independent trials.

Enzyme-linked immunosorbent assay (ELISA)

BDNF was measured using an ELISA kit according to the manufacturer’s protocol (Enzyme ImmunoAssay Systems; Promega, Madison, WI, USA). Neurons at 14 days in vitro were treated with 5 μM oAβ or 100 pM FTY720-P for 24 h. Cell lysates were obtained with lysis buffer and soluble fractions were collected following centrifugation for 5 min at 10,000 g, Assays were carried out in three independent trials.

Drug treatment

Neurons at 14 days in vitro were treated with 1–100 pM FTY720-P or 250–1000 pg/ml mouse recombinant BDNF (Promega) from 3 h before oAβ1-42 stimulation. To block BDNF-TrkB signaling, 0.01–1 μg/ml BDNF scavenger (TrkB Fc chimera, R&D systems, Minneapolis, MN, USA) or 0.001–10 μg/ml TrkB inhibitor (ANA-12; Sigma, St. Louis, MO, USA), and 1 μM ERK1/2 inhibitor (U0126; Millipore, Billerica, MA, USA) was added from 1 h before FTY720-P treatment. After stimulation
with 5 μM αβ1-42 for 24 h, neuronal survival was assessed as below.

**Immunocytochemistry**

Neurons were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100, and blocked with 5% normal goat serum in phosphate-buffered saline for 1 h at room temperature. Neurons were stained with rabbit anti-S1P1 polyclonal antibodies (1:100; Cayman Chemical), rabbit anti-S1P2 polyclonal antibodies (1:100; Cayman Chemical), rabbit anti-S1P3 polyclonal antibodies (1:100; Cayman Chemical), rabbit anti-S1P4 polyclonal antibodies (1:100; Cayman Chemical), rabbit anti-S1P5 polyclonal antibodies (1:100; Cayman Chemical), rabbit antimicrotubule-associated protein 2 (MAP-2) polyclonal antibodies (1:1000; Millipore, Billerica, MA, USA) and Aβ was stained with mouse anti-Aβ monoclonal antibody (4G8) (1:1000; Chemicon, Billerica, MA, USA). The samples were observed using a deconvolution fluorescence microscope system (BZ-8000; Keyence, Osaka, Japan).

**Assessments of neuronal survival**

Neuronal survival was assessed by the number of MAP-2-positive neurons and 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8) assay. To count MAP-2-positive neurons and normalized based on results observed with untreated neurons as described previously [24]. Viable neurons stained strongly with an anti-MAP-2 antibody, whereas damaged neurons showed much weaker staining. The number of MAP-2-positive neurons was counted in 10 random fields per well. More than 200 cells were examined in three independent trials. The number of untreated viable neurons was normalized to 100%.

WST-8 assay was carried out in six independent trials using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the instructions of the manufacturer.
Figure 2. FTY720-P suppressed oAβ-induced neurotoxicity. (A) Western blotting image for characterization of oAβ. Data showed Aβ1-42 oligomerization composed with small (monomer, dimer, 3-mer, 4-mer, 8-mer, and 12-mer) and large oligomers. (B) Fluorescent microscopic images of mouse primary cortical neuron cultures. Treatment with FTY720-P was neuroprotective against oAβ-mediated toxicity. Neurons were stained with anti–MAP-2 (green) antibodies and Aβ was stained with 4G8 antibodies (red). Scale bar: 50 μm. NT, no treatment; oAβ, 5 μM Aβ1-42 treatment. (C) Relative neuronal survival. The number of viable neurons (MAP-2–positive neurons) was quantified relative to results observed with untreated neurons. FTY720-P rescued neurons against oAβ-mediated toxicity. Aβ1-42 treatment. *, P<0.001; †, P<0.001. Values are means ± SEM (n = 3). (D) WST-8 assay. FTY720-P enhanced neuronal survival against oAβ–mediated toxicity. Aβ1-42 treatment. *, P<0.001; †, P<0.001. Values are means ± SEM (n = 6).

doi:10.1371/journal.pone.0061988.g002
manufacture's instruction. Absorbance at 450 nm was measured in a multiple plate reader.

**Statistical analysis**

Statistical significance was analyzed with Student's *t*-test or one-way analysis of variance followed by post-hoc Tukey's test using GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA, USA).

**Results**

**Neurons express S1PRs**

First, we examined S1PR expression on primary cortical neurons. RT-PCR analysis revealed that cortical neurons constitutively expressed all S1PR subtypes regardless of stimulation with 5 μM oΔβ1-42 (Figure 1A). Immunostaining for S1PRs depicted that cortical neurons expressed all S1PR subtypes (Figure 1B). Western blotting analysis also showed that cortical neurons constitutively expressed all S1PR subtypes (Figure 1C, arrowheads), which is consistent with the RT-PCR data, although multiple non-specific bands were also detected. Treatment with 5 μM oΔβ1-42 did not alter the expression levels of S1PRs.

**FTY720-P suppresses oΔβ1-42-induced neurotoxicity**

We confirmed the oligomerization of oΔβ1-42 (Figure 2A). As we had shown previously [4,24], Western blotting data demonstrated that oΔβ1-42 we used mainly consisted oligomers, but not fibrillar Δβ. We then examined the effects of FTY720-P on oΔβ1-42 induced neurotoxicity. Treatment with 1–100 pM FTY720-P

---

**Figure 3. FTY720-P enhanced BDNF production.** (A) qRT-PCR data for neurotrophic factors in neurons. FTY720-P significantly upregulated mRNA expression levels of BDNF. *, *P*<0.05. Values are means ± SEM (n = 6). (B) Western blotting data for BDNF production. FTY720-P significantly enhanced neuronal BDNF production. BDNF levels are quantified relative to those in untreated neurons. NT, no treatment. *, *P*<0.05. Values are means ± SEM (n = 6). (C) ELISA data for BDNF production. BDNF levels significantly increased in response to FTY720-P. NT, no treatment. †, P<0.001. Values are means ± SEM (n = 3).

doi:10.1371/journal.pone.0061988.g003
alone did not affect neuronal survival (Figure 2B, 1 pM FTY720-P, 10 pM FTY720-P, and 100 pM FTY720-P, Figure 2G and 2D, green columns). Next, neuronal cultures were treated with 1–100 pM FTY720-P for 3 h prior to the addition of 5 μM αAb1-42 for 24 h. Treatment with 5 μM αAb1-42 for 24 h resulted in severe neurotoxicity (Figure 2B, αAb; Figure 2C and 2D, black columns), which agrees with previous reports [3,4,25]. However, treatment with 100 pM FTY720-P protected the neurons against αAb–induced toxicity (Figure 2B, αAb+100 pM FTY720-P, Figure 2G and 2D, red columns).

**FTY720-P induces BDNF production**

Next, we examined whether FTY720-P exerts neuroprotective effects by upregulating neurotrophic factors like microglia [19].
We assessed mRNA expression levels of neuronal BDNF, NGF, and NT-3 using qPCR. Interestingly, FTY720-P increased mRNA expression levels of BDNF, whereas it did not significantly affect those of NGF and NT-3 (Figure 3A). Neuronal BDNF production was also significantly enhanced by 100 pM FTY720-P based on results obtained with Western blotting and ELISAs (Figure 3B, C).

Figure 5. Activation of TrkB by BDNF is critical for the neuroprotective effects of FTY720-P. (A) Fluorescent microscopic images of mouse primary cortical neuron cultures. The TrkB inhibitor ANA-12 ablated the neuroprotective effects of FTY720-P against oAβ-induced neurotoxicity. Neurons were stained with anti–MAP-2 antibodies (green) and Aβ was stained with 4G8 antibodies (red). Scale bar: 50 μm. NT, no treatment; oAβ 5 μM oAβ1-42treatment; FTY720-P, 100 pM FTY720-P treatment. (B) Relative neuronal survival. The number of viable neurons (MAP-2–positive neurons) was quantified relative to results observed in untreated neurons. TrkB inhibition almost completely inhibited the neuroprotective effects of FTY720-P. oAβ 5 μM oAβ1-42treatment; FTY720-P, 100 pM FTY720-P treatment. *, P<0.001; †, P<0.001; ‡, P<0.001. Values are means ± SEM (n = 4). (C) WST-8 assay. Blocking TrkB almost completely reversed the neuroprotective effects of FTY720-P, whereas it did not enhance oAβ-mediated neurotoxicity. oAβ 5 μM oAβ1-42treatment; FTY720-P, 100 pM FTY720-P treatment. *, P<0.001; †, P<0.001; ‡, P<0.001. Values are means ± SEM (n = 6).

doi:10.1371/journal.pone.0061988.g005
Neuroprotective effects of FTY720-P depend on BDNF-TrkB signaling

BDNF exerts neuroprotective effects through its receptor TrkB [26]. To examine whether FTY720-P is protective via neuronal BDNF expression, we blocked BDNF-TrkB signaling using a TrkB–Fc chimera as a BDNF scavenger and ANA-12 as a TrkB inhibitor.

We confirmed that treatment with BDNF scavenger alone did not alter neuronal survival (Figure 4A, 0.1 μg/ml BDNF scavenger and 1 μg/ml BDNF scavenger; Figure 4B and 4C, green columns). The BDNF scavenger dose-dependently suppressed the neuroprotective effects of FTY720-P (Figure 4A, oAβ+FTY720-P+0.01 μg/ml BDNF scavenger, oAβ+FTY720-P+0.1 μg/ml BDNF scavenger and oAβ+FTY720-P+1 μg/ml BDNF scavenger; Figure 4B and 4C, blue columns). BDNF scavenger per se did not enhance oAβ-mediated neurotoxicity (Figure 4C, gray column). Moreover, addition of BDNF prevented oAβ-mediated neurotoxicity to the same extent of FTY720-P (Figure 4C, yellow and orange columns).

We confirmed that treatment with the TrkB inhibitor ANA-12 alone did not alter neuronal survival (Figure 4A, 0.1 μM ANA-12 and 10 μM ANA-12; Figure 4B and 4C, green columns). 10 μM ANA-12 almost completely ablated the neuroprotective effects of FTY720-P (Figure 5A, oAβ+FTY720-P+10 μM ANA-12; Figure 5B and 5C, blue columns). ANA-12 per se did not enhance oAβ-mediated neurotoxicity (Figure 5C, gray column). These results demonstrated that the neuroprotective effects of FTY720-P depend on BDNF-TrkB signaling.

Figure 6. The neuroprotective effect of FTY720-P require ERK1/2 signaling. (A) Fluorescent microscopic images of mouse primary cortical neuron cultures. ERK1/2 inhibitor U0126 almost completely suppressed FTY720-P–mediated protection against oAβ-induced neurotoxicity. Neurons were stained with anti–MAP-2 antibodies (green) and Aβ was stained with 4G8 antibodies (red). Scale bar: 50 μm. (B) Relative neuronal survival. The number of viable neurons (MAP-2–positive neurons) was quantified relative to results observed in untreated neurons. ERK1/2 inhibition almost completely ablated the neuroprotective effects of FTY720-P. oAβ 5 μM oAβ1-42 treatment; FTY720-P, 100 pM FTY720-P treatment. *, P<0.001; †, P<0.001; ‡, P<0.001. Values are means ± SEM (n = 3). (C) WST-8 assay. Blocking ERK1/2 almost completely canceled the neuroprotective effects of FTY720-P, whereas it did not enhance oAβ–mediated neurotoxicity. oAβ 5 μM oAβ1-42 treatment; FTY720-P, 100 pM FTY720-P treatment. *, P<0.001; †, P<0.001; ‡, P<0.001. Values are means ± SEM (n = 6).

doi:10.1371/journal.pone.0061988.g006

Neuroprotective effects of FTY720-P depend on BDNF-TrkB signaling

The ERK1/2 pathway contributes to FTY720-P–mediated neuroprotection

The ERK1/2 pathway is a major downstream effector of TrkB signaling [27]. We examined the role of the ERK1/2 pathway in FTY720-P–mediated neuroprotection. Inhibition of ERK1/2 almost completely suppressed the neuroprotective effects of FTY720-P against oAβ-induced neurotoxicity (Figure 6A, oAβ+FTY720-P+1 μM U0126; Figure 6B and 6C, blue columns), whereas U0126 per se did not exhibit neurotoxicity nor enhance...
αβ-mediated neurotoxicity (Figure 6C, green and gray columns). These results revealed that FTY720-P-mediated neuroprotection depended on ERK1/2 signaling.

Discussion

This is the first report showing that FTY720-P is protective against αβ42-induced neurotoxicity. We have demonstrated that FTY720-P enhances the production of BDNF, which activates TrkB and ERK1/2 signaling. Although αβ-stimulated mononuclear cells reportedly show increased mRNA expression levels of S1P1 and S1P5 [28], whether S1PR subtypes regardless of Aβ transmission, and synaptic plasticity [32–34]. Several reports have including contributions to cell survival, axon growth, neuronal transmission, and synaptic plasticity [32–34]. Several reports have documented that BDNF and TrkB contribute to long-term potentiation and memory formation [35–36]. Decreased BDNF-TrkB signaling induces deficiencies in spatial memory [39], whereas overexpression of full-length TrkB can enhance learning and memory [40]. Moreover, BDNF expression levels are lower in patients with AD [41, 42]. Thus, BDNF-TrkB signaling may play an important role in the pathology of AD. In this study, we demonstrated that BDNF-TrkB signaling is critical for the neuroprotective effects of FTY720-P against αβ42-induced neurotoxicity. We believe that treatment with FTY720 and resulting increases in BDNF expression are a promising therapeutic strategy for AD. Recently, FTY720-P was shown to improve spinal cord injuries via nonimmunologic mechanisms [43]. Furthermore, FTY720-P injections induced BDNF production and improved disease symptoms in mouse models of Rett syndrome [44]. These two papers corroborate the potential therapeutic utility of our approach.

In conclusion, FTY720 appears to be a promising therapeutic agent against not only multiple sclerosis but also various neurodegenerative diseases, including AD.

Author Contributions

Conceived and designed the experiments: HT AS. Performed the experiments: YD HT HH TH. Analyzed the data: YD HT TM AS. Contributed reagents/materials/analysis tools: JK SJ BP YS. Wrote the paper: YD HT AS.

References

1. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behv Brain Res 192: 106–113.
2. Waskle DM, Teplow DB (2012) Alzheimer’s disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 107: 101–124.
3. Deshpande A, Mina E, Gabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26: 6011–6018.
4. Doi V, Mizuno T, Makl V, Jin S, Mizuguchi H, et al. (2009) Microglia activated with the toll-like receptor 9 ligand CpG alternate oligomeric amyloid [beta] neurotoxicity in vitro and in vivo models of Alzheimer’s disease. Am J Pathol 175: 2121–2132.
5. De Felice FG, Velasco PD, Lambert MP, Viola K, Fernandez SJ, et al. (2007) Abeta oligomers induce neuronal oxidative stress through an Nethylid-A receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282: 11590–11601.
6. Brinkmann V, Billich A, Baumrucker T, Heiming P, Schmouder R, et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 383–892.
7. Chen J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91–101.
8. Cohen JA, Chen J (2011) Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759–777.
9. Pelletier D, Haller DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366: 339–347.
10. Adeki A, Kohara T, Nakao N, Arita M, Chiha K, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediol: discovery of a novel immunosuppressant. FTY720. Bioorg Med Chem 3: 853–856.
11. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346–349.
12. Matsubian M, Lo CG, Cimmom G, Leneski MJ, Xu Y, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on SIP receptor 1. Nature 427: 355–360.
13. Pinchescher DE, Olschensn AF, Odermann B, Brinkmann V, Hengartner H, et al. (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164: 5761–5770.
14. Brinkmann V (2007) Sphingosine-1-phosphate receptors in health and disease: mechanistic insight from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84–105.
15. Brinkmann V, Davis MD, Heise CE, Albert R, Cotens S, et al. (2002) The immum modulator FTY720 targets sphingosine-1-phosphate receptors. J Biol Chem 277: 21453–21457.
16. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilhe G, et al. (2008) Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77–93.
17. Miron VE, Ludwin SK, Darlington FJ, Jarjour AA, Soliven B, et al. (2010) Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 176: 2682–2694.
18. Chai JW, Tegard SE, Herr DR, Rivera R, Lee CW, et al. (2011) Fingolimod (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine-1-phosphate receptor 1 (SIP1) modulation. Proc Natl Acad Sci U S A 108: 1751–1756.
19. Noda H, Takachiz H, Mizuno T, Sazumura A (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol.
20. Hazada J, Foley M, Moskovitz MA, Wacher C (2004) Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 88: 1026–1039.
21. Kinura A, Ohmorii T, Ohkawa R, Madoiwa S, Mimuro J, et al. (2007) Essential roles of sphingosine-1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25: 115–124.
22. Dalgren KN, Manelli AM, Sine WB Jr, Baker LR, Krafl GA, et al. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046–32053.
23. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawakomachi K, et al. (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280: 10444–10454.
24. Mizuno T, Doi Y, Mizuguchi H, Jin S, Noda M, et al. (2011) Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate amyloid-beta-mimetic toxicity. Am J Pathol 179: 1606–2007.
25. Manelli AM, Boltbich LC, Sullivan PM, LaDu MJ (2007) Abeta2 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging 28: 1139–1147.
26. Soppe D, Escandon E, Maragos J, Middlemas DS, Reid SW, et al. (1991) The sphingosine receptor binds to the tumor necrosis factor and regulates its responses. EMBO J 10: 2125–2131.
27. Osclub M, Muldershausen F, Dev KK (2007) Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via SIP receptors. Neuropharmacology 52: 1210–1212.
28. Kanaev NC, Lindner J, Feistritzer C, Sturn DH, Mosheimer BA, et al. (2004) FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J 18: 1309–1311.
29. Kannev JM, Lauterborn JC, Yan Q, Gall CM, Varon S (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 17: 2295–2313.

PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e61988
30. Yan Q, Radeke MJ, Matheson CR, Talvenheim J, Welcher AA, et al. (1997) Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 378: 135–157.
31. Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, et al. (1997) Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 78: 431–448.
32. Drake CT, Milner TA, Patterson SL (1999) Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. J Neurosci 19: 8009–8026.
33. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677–736.
34. Yoshii A, Constantine-Paton M (2010) Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70: 304–322.
35. Kemppainen S, Rautamaki T, Jeronimo-Santos A, Lavasseur G, Autio H, et al. (2012) Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging 33: 1122 e1123–1139.
36. Lu Y, Christian K, Lu B (2008) BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 90: 312–323.
37. Mizuno M, Yamada K, He J, Nakajima A, Nabeshima T (2003) Involvement of BDNF receptor TrkB in spatial memory formation. Learn Mem 10: 108–115.
38. Rex CS, Lin CY, Kramar EA, Chen LY, Gall CM, et al. (2007) Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci 27: 3017–3029.
39. Minichiello L (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10: 850–860.
40. Koponen E, Voikar V, Riekki R, Saarelainen T, Rauramaa T, et al. (2004) Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol Cell Neurosci 26: 166–181.
41. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, et al. (1999) BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58: 729–739.
42. Phillips HS, Hains JM, Armanini M, Laramore GR, Johnson SA, et al. (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7: 695–702.
43. Norimatsu Y, Ohmori T, Kimura A, Madoiwa S, Mimuro J, et al. (2012) FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. Am J Pathol 180: 1625–1635.
44. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, et al. (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 109: 14230–14235.